calcium acetate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
4287 62-54-4

Description:

MoleculeDescription

Synonyms:

  • calcium acetate
  • acetic acid calcium salt
  • calcium diacetate
  • calcium acetate anhydrous
a principal compound used as phosphate binders in patients with chronic renal failure; used like sevelamer
  • Molecular weight: 158.17
  • Formula: C4H6CaO4
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA: 40.13
  • ALOGS:
  • ROTB: None

Drug dosage:

DoseUnitRoute
6 g O

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
May 6, 1982 FDA B BRAUN

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Nephrogenic systemic fibrosis 255.72 14.84 72 8953 4250 50591849
Skin induration 117.20 14.84 36 8989 2875 50593224
Peritonitis bacterial 112.00 14.84 39 8986 4622 50591477
Skin hypertrophy 94.48 14.84 31 8994 3064 50593035
Calciphylaxis 91.03 14.84 29 8996 2609 50593490
Skin tightness 80.93 14.84 29 8996 3734 50592365
Skin fibrosis 58.55 14.84 16 9009 843 50595256
Chronic kidney disease 54.84 14.84 50 8975 39721 50556378
Peritonitis 54.17 14.84 34 8991 15452 50580647
Skin hyperpigmentation 48.31 14.84 22 9003 5254 50590845
Dialysis 46.89 14.84 26 8999 9412 50586687
Fibrosis 45.29 14.84 19 9006 3728 50592371
Blood phosphorus increased 44.82 14.84 17 9008 2565 50593534
Haemodialysis 44.20 14.84 24 9001 8338 50587761
Hypervolaemia 43.08 14.84 36 8989 25463 50570636
Blood parathyroid hormone increased 39.69 14.84 16 9009 2838 50593261
Hypercalcaemia 37.46 14.84 32 8993 23320 50572779
Joint contracture 36.29 14.84 13 9012 1671 50594428
Drug ineffective 31.37 14.84 62 8963 819271 49776828
Hypocalcaemia 29.91 14.84 30 8995 26786 50569313
Haemodialysis complication 29.89 14.84 7 9018 196 50595903
Milk-alkali syndrome 29.82 14.84 9 9016 676 50595423
Aplasia pure red cell 27.70 14.84 14 9011 4201 50591898
Joint range of motion decreased 26.93 14.84 24 9001 18488 50577611
Peau d'orange 26.67 14.84 6 9019 140 50595959
Scar 24.90 14.84 19 9006 11799 50584300
Extremity contracture 24.52 14.84 9 9016 1239 50594860
Oedema peripheral 23.84 14.84 72 8953 157889 50438210
End stage renal disease 23.66 14.84 14 9011 5723 50590376
Skin discolouration 23.34 14.84 29 8996 32728 50563371
Azotaemia 22.57 14.84 12 9013 3996 50592103
Therapeutic response decreased 21.90 14.84 34 8991 47197 50548902
Peritoneal dialysis complication 21.31 14.84 8 9017 1173 50594926
Blood erythropoietin decreased 20.82 14.84 3 9022 3 50596096
Anti-erythropoietin antibody positive 20.71 14.84 6 9019 391 50595708
Cardiac failure congestive 20.50 14.84 46 8979 84336 50511763
Hyperparathyroidism secondary 20.27 14.84 8 9017 1342 50594757
Haemoglobin decreased 20.15 14.84 59 8966 127157 50468942
Drug intolerance 20.10 14.84 7 9018 219097 50377002
Skin plaque 19.91 14.84 13 9012 6315 50589784
Hyperparathyroidism 18.80 14.84 9 9016 2405 50593694
Unresponsive to stimuli 18.52 14.84 25 9000 30584 50565515
Renal failure 18.39 14.84 51 8974 106582 50489517
Sinusitis 18.34 14.84 4 9021 170554 50425545
Sepsis 17.67 14.84 58 8967 132867 50463232
Product use issue 17.14 14.84 3 9022 149472 50446627
Hypotension 17.03 14.84 85 8940 235384 50360715
Emotional distress 16.72 14.84 23 9002 28640 50567459
Fungal peritonitis 15.25 14.84 5 9020 492 50595607
Anhedonia 15.16 14.84 13 9012 9511 50586588
Deformity 15.07 14.84 12 9013 7928 50588171

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Nephrogenic systemic fibrosis 221.15 16.36 70 8298 3872 29562287
Peritonitis bacterial 151.04 16.36 58 8310 5698 29560461
Skin induration 121.52 16.36 38 8330 2016 29564143
Skin hypertrophy 111.64 16.36 37 8331 2366 29563793
Skin tightness 94.28 16.36 31 8337 1933 29564226
Joint contracture 84.75 16.36 28 8340 1772 29564387
Joint range of motion decreased 78.48 16.36 37 8331 6017 29560142
Skin fibrosis 69.61 16.36 21 8347 986 29565173
Scar 57.84 16.36 29 8339 5390 29560769
Peritonitis 56.75 16.36 41 8327 14783 29551376
Peritoneal dialysis complication 48.80 16.36 18 8350 1579 29564580
Fibrosis 48.69 16.36 20 8348 2339 29563820
Hypervolaemia 46.42 16.36 39 8329 17506 29548653
Extremity contracture 45.32 16.36 14 8354 712 29565447
Calciphylaxis 40.75 16.36 14 8354 998 29565161
Blood parathyroid hormone increased 40.40 16.36 15 8353 1340 29564819
Anhedonia 37.26 16.36 24 8344 7176 29558983
Chronic kidney disease 36.25 16.36 48 8320 36368 29529791
Emotional distress 32.92 16.36 29 8339 13866 29552293
Aplasia pure red cell 32.68 16.36 20 8348 5471 29560688
Dialysis 31.87 16.36 25 8343 10183 29555976
Deformity 28.82 16.36 12 8356 1452 29564707
Haemodialysis 28.14 16.36 23 8345 9931 29556228
Joint stiffness 27.02 16.36 22 8346 9451 29556708
Therapeutic response decreased 26.81 16.36 34 8334 24677 29541482
Skin hyperpigmentation 26.71 16.36 14 8354 2850 29563309
Injury 25.23 16.36 29 8339 19017 29547142
Cardiac arrest 24.49 16.36 66 8302 85525 29480634
Peau d'orange 23.79 16.36 6 8362 143 29566016
Complication associated with device 23.69 16.36 16 8352 5175 29560984
Renal failure 23.19 16.36 80 8288 118519 29447640
Skin discolouration 23.05 16.36 25 8343 15384 29550775
Fungal peritonitis 21.88 16.36 8 8360 684 29565475
Haemoglobin decreased 21.09 16.36 73 8295 108302 29457857
Blood potassium increased 20.58 16.36 23 8345 14628 29551531
Mobility decreased 19.75 16.36 30 8338 25750 29540409
Arteriovenous fistula occlusion 19.20 16.36 5 8363 136 29566023
Choreoathetosis 18.87 16.36 8 8360 1012 29565147
Azotaemia 18.34 16.36 13 8355 4544 29561615
Hyperphosphataemia 18.23 16.36 10 8358 2228 29563931
Transferrin saturation increased 17.25 16.36 4 8364 66 29566093
Refractory cytopenia with unilineage dysplasia 17.14 16.36 6 8362 452 29565707
Anti-erythropoietin antibody positive 16.76 16.36 7 8361 853 29565306

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Nephrogenic systemic fibrosis 339.45 13.50 100 13633 5792 64479207
Peritonitis bacterial 258.23 13.50 90 13643 8953 64476046
Skin induration 177.01 13.50 56 13677 4119 64480880
Skin hypertrophy 168.47 13.50 55 13678 4474 64480525
Skin tightness 147.88 13.50 51 13682 4910 64480089
Calciphylaxis 130.42 13.50 42 13691 3270 64481729
Peritonitis 110.64 13.50 68 13665 24955 64460044
Skin fibrosis 102.90 13.50 29 13704 1430 64483569
Joint contracture 97.86 13.50 31 13702 2288 64482711
Chronic kidney disease 76.52 13.50 77 13656 57842 64427157
Peritoneal dialysis complication 74.61 13.50 25 13708 2203 64482796
Joint range of motion decreased 74.06 13.50 48 13685 19295 64465704
Hypervolaemia 72.05 13.50 62 13671 38223 64446776
Haemodialysis 64.45 13.50 42 13691 17035 64467964
Dialysis 57.54 13.50 39 13694 16881 64468118
Fibrosis 56.33 13.50 25 13708 4703 64480296
Scar 55.64 13.50 35 13698 13363 64471636
Blood parathyroid hormone increased 52.11 13.50 21 13712 3113 64481886
Skin hyperpigmentation 51.48 13.50 26 13707 6525 64478474
Extremity contracture 38.16 13.50 14 13719 1611 64483388
Skin discolouration 37.87 13.50 42 13691 35213 64449786
Blood phosphorus increased 37.03 13.50 19 13714 4927 64480072
Completed suicide 36.55 13.50 3 13730 224411 64260588
Aplasia pure red cell 36.02 13.50 21 13712 6993 64478006
Peau d'orange 35.34 13.50 9 13724 300 64484699
Hypercalcaemia 34.74 13.50 38 13695 31378 64453621
Anhedonia 33.80 13.50 26 13707 13680 64471319
Renal failure 33.80 13.50 100 13633 181588 64303411
End stage renal disease 32.91 13.50 23 13710 10452 64474547
Azotaemia 32.16 13.50 20 13713 7482 64477517
Hypocalcaemia 32.15 13.50 42 13691 41711 64443288
Haemodialysis complication 30.58 13.50 8 13725 297 64484702
Joint stiffness 30.57 13.50 35 13698 30369 64454630
Emotional distress 30.50 13.50 38 13695 36000 64448999
Drug ineffective 30.23 13.50 86 13647 840161 63644838
Deformity 30.10 13.50 18 13715 6279 64478720
Fungal peritonitis 29.00 13.50 10 13723 961 64484038
Unresponsive to stimuli 28.86 13.50 44 13689 50349 64434650
Haemoglobin decreased 26.92 13.50 97 13636 194966 64290033
Hyperphosphataemia 26.12 13.50 14 13719 3967 64481032
Cardiac arrest 26.02 13.50 82 13651 153982 64331017
Pulmonary calcification 24.31 13.50 7 13726 373 64484626
Anti-erythropoietin antibody positive 24.12 13.50 8 13725 683 64484316
Hypotension 23.50 13.50 150 13583 380824 64104175
Oedema peripheral 22.86 13.50 97 13636 210220 64274779
Arteriovenous fistula thrombosis 22.02 13.50 7 13726 522 64484477
Arteriovenous fistula occlusion 21.77 13.50 7 13726 542 64484457
Transferrin saturation increased 21.05 13.50 5 13728 124 64484875
Off label use 20.40 13.50 68 13665 632738 63852261
Arteriovenous fistula operation 20.21 13.50 6 13727 356 64484643
Skin plaque 19.97 13.50 16 13717 8924 64476075
Milk-alkali syndrome 19.86 13.50 8 13725 1185 64483814
Complication associated with device 19.81 13.50 20 13713 15060 64469939
Cardiac failure congestive 19.79 13.50 67 13666 130513 64354486
Blood potassium increased 19.79 13.50 26 13707 25954 64459045
Transferrin saturation decreased 19.47 13.50 7 13726 760 64484239
Injury 19.17 13.50 39 13694 55953 64429046
Asthenia 18.60 13.50 155 13578 427889 64057110
Serum ferritin increased 18.59 13.50 15 13718 8453 64476546
Choreoathetosis 18.37 13.50 8 13725 1439 64483560
Sepsis 18.28 13.50 97 13636 230244 64254755
Arteriovenous fistula site complication 18.26 13.50 7 13726 909 64484090
Ultrafiltration failure 17.79 13.50 5 13728 244 64484755
Drug intolerance 17.63 13.50 9 13724 187983 64297016
Kidney transplant rejection 17.07 13.50 15 13718 9496 64475503
Skin disorder 17.03 13.50 25 13708 27655 64457344
Treatment noncompliance 16.96 13.50 32 13701 43450 64441549
Mobility decreased 16.66 13.50 48 13685 85792 64399207
Mental status changes 15.74 13.50 38 13695 61124 64423875
Sclerodactylia 15.63 13.50 4 13729 136 64484863
Peripheral swelling 15.56 13.50 13 13720 209140 64275859
Pulseless electrical activity 15.12 13.50 16 13717 12723 64472276
Hyperparathyroidism secondary 14.74 13.50 8 13725 2322 64482677
Product use issue 14.62 13.50 7 13726 151708 64333291
Nephrogenic anaemia 14.59 13.50 9 13724 3316 64481683
Contraindicated product administered 13.87 13.50 3 13730 107826 64377173
Brown tumour 13.82 13.50 3 13730 49 64484950
Rheumatoid arthritis 13.79 13.50 9 13724 164285 64320714
Peritoneal cloudy effluent 13.78 13.50 4 13729 219 64484780
Hospitalisation 13.58 13.50 41 13692 75166 64409833

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC V03AE07 VARIOUS
ALL OTHER THERAPEUTIC PRODUCTS
ALL OTHER THERAPEUTIC PRODUCTS
Drugs for treatment of hyperkalemia and hyperphosphatemia
CHEBI has role CHEBI:38161 Chelating agent
MeSH PA D002614 Chelating Agents
MeSH PA D064449 Sequestering Agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Hypocalcemia indication 5291005
Hyperkalemia indication 14140009
Hypermagnesemia indication 66978005
Hypocalcemic tetany indication 190869004
Disorder of electrolytes indication 237840007
Cardiac arrest indication 410429000 DOID:0060319
Renal Osteodystrophy with Hyperphosphatemia indication
Neonatal hypocalcemic tetany off-label use 18442000
Poisoning by digitalis glycoside contraindication 12876009
Sarcoidosis contraindication 31541009 DOID:11335
Dehydration contraindication 34095006
End stage renal disease contraindication 46177005 DOID:784
Humoral hypercalcemia of malignancy contraindication 47709007
Heart disease contraindication 56265001 DOID:114
Diarrhea contraindication 62315008
Hypercalcemia contraindication 66931009 DOID:12678
Hyperparathyroidism contraindication 66999008 DOID:13543
Ventricular fibrillation contraindication 71908006
Hypercalciuria contraindication 71938000
Kidney disease contraindication 90708001 DOID:557
Kidney stone contraindication 95570007




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
667MG/5ML PHOSLYRA FRESENIUS MEDCL N022581 April 18, 2011 RX SOLUTION ORAL 8592480 July 20, 2027 USE OF PHOSLYRA FOR REDUCTION OF SERUM PHOSPHOROUS IN PATIENTS
667MG/5ML PHOSLYRA FRESENIUS MEDCL N022581 April 18, 2011 RX SOLUTION ORAL 9089528 July 20, 2027 USE OF PHOSLYRA FOR REDUCTION OF SERUM PHOSPHOROUS IN PATIENTS
667MG/5ML PHOSLYRA FRESENIUS MEDCL N022581 April 18, 2011 RX SOLUTION ORAL 8591938 Feb. 23, 2030 USE OF PHOSLYRA FOR REDUCTION OF SERUM PHOSPHOROUS IN PATIENTS

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
4018721 VUID
N0000147026 NUI
D00931 KEGG_DRUG
4018721 VANDF
C0717537 UMLSCUI
CHEBI:59199 CHEBI
CHEMBL1200800 ChEMBL_ID
DB00258 DRUGBANK_ID
C120662 MESH_SUPPLEMENTAL_RECORD_UI
Y882YXF34X UNII
6116 PUBCHEM_CID
214342 RXNORM
118 MMSL
4329 MMSL
d03689 MMSL
000772 NDDF
116118002 SNOMEDCT_US
387019008 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Calcium Acetate HUMAN PRESCRIPTION DRUG LABEL 1 0054-0088 CAPSULE 667 mg ORAL ANDA 25 sections
ProcalAmine HUMAN PRESCRIPTION DRUG LABEL 22 0264-1915 INJECTION 0.03 g INTRAVENOUS NDA 24 sections
Calcium Acetate HUMAN PRESCRIPTION DRUG LABEL 1 0615-8364 CAPSULE 667 mg ORAL ANDA 25 sections
Calcium Acetate HUMAN PRESCRIPTION DRUG LABEL 1 0781-2081 CAPSULE 667 mg ORAL NDA authorized generic 26 sections
Calcium Acetate HUMAN PRESCRIPTION DRUG LABEL 1 0781-2672 CAPSULE 667 mg ORAL NDA authorized generic 26 sections
CALCIUM ACETATE HUMAN PRESCRIPTION DRUG LABEL 1 0904-6668 CAPSULE 667 mg ORAL ANDA 25 sections
Calcium Acetate HUMAN PRESCRIPTION DRUG LABEL 1 0904-7119 CAPSULE 667 mg ORAL ANDA 25 sections
Calcium Acetate HUMAN PRESCRIPTION DRUG LABEL 1 10135-629 CAPSULE 667 mg ORAL ANDA 26 sections
Calcium Acetate HUMAN PRESCRIPTION DRUG LABEL 1 16571-813 CAPSULE 667 mg ORAL ANDA 19 sections
Calcium Acetate HUMAN PRESCRIPTION DRUG LABEL 1 17856-0088 CAPSULE 667 mg ORAL ANDA 24 sections
Calcium Acetate HUMAN PRESCRIPTION DRUG LABEL 1 17856-0191 CAPSULE 667 mg ORAL ANDA 27 sections
Calcium Acetate HUMAN PRESCRIPTION DRUG LABEL 1 17856-0377 CAPSULE 667 mg ORAL ANDA 17 sections
CALCIUM ACETATE HUMAN PRESCRIPTION DRUG LABEL 1 23155-531 CAPSULE 667 mg ORAL ANDA 25 sections
CALCIUM ACETATE HUMAN PRESCRIPTION DRUG LABEL 1 23155-531 CAPSULE 667 mg ORAL ANDA 25 sections
CALCIUM ACETATE HUMAN PRESCRIPTION DRUG LABEL 1 23155-621 TABLET 667 mg ORAL ANDA 16 sections
Calcium Acetate HUMAN PRESCRIPTION DRUG LABEL 1 24689-793 CAPSULE 667 mg ORAL ANDA 19 sections
Calcium Acetate HUMAN PRESCRIPTION DRUG LABEL 1 29033-026 CAPSULE 667 mg ORAL ANDA 24 sections
Calcium Acetate HUMAN PRESCRIPTION DRUG LABEL 1 31722-377 CAPSULE 667 mg ORAL ANDA 17 sections
Calcium Acetate HUMAN PRESCRIPTION DRUG LABEL 1 31722-393 TABLET 667 mg ORAL ANDA 17 sections
PhosLo HUMAN PRESCRIPTION DRUG LABEL 1 49230-640 CAPSULE 667 mg ORAL NDA 24 sections
Phoslyra HUMAN PRESCRIPTION DRUG LABEL 1 49230-643 SOLUTION 667 mg ORAL NDA 26 sections
CALCIUM ACETATE HUMAN PRESCRIPTION DRUG LABEL 1 50436-0621 TABLET 667 mg ORAL ANDA 16 sections
Aluminum Acetate Astringent HUMAN OTC DRUG LABEL 2 51224-153 POWDER, FOR SOLUTION 839 mg TOPICAL OTC MONOGRAPH FINAL 13 sections
Calcium Acetate HUMAN PRESCRIPTION DRUG LABEL 1 51293-825 CAPSULE 667 mg ORAL ANDA 16 sections
Calcium Acetate HUMAN PRESCRIPTION DRUG LABEL 1 53746-590 CAPSULE 667 mg ORAL ANDA 25 sections
Calcium Acetate HUMAN PRESCRIPTION DRUG LABEL 1 53808-0216 CAPSULE 667 mg ORAL ANDA 18 sections
Calcium Acetate HUMAN PRESCRIPTION DRUG LABEL 1 53808-0905 CAPSULE 667 mg ORAL NDA AUTHORIZED GENERIC 26 sections
Calcium Acetate HUMAN PRESCRIPTION DRUG LABEL 1 53808-1001 CAPSULE 667 mg ORAL ANDA 17 sections
Calcium Acetate HUMAN PRESCRIPTION DRUG LABEL 1 53808-1103 CAPSULE 667 mg ORAL ANDA 25 sections
Phoslo HUMAN PRESCRIPTION DRUG LABEL 1 54868-3460 CAPSULE 667 mg ORAL NDA 11 sections